Infigratinib is in phase II clinical trials for the treatment of melanoma, recurrent glioblastoma.
Phase II clinical trials are also ongoing for the treatment of cancer with FGFR mutation, such as advanced solid malignancies with FGFR mutation, advanced or metastatic cholangiocarcinoma with FGFR genetic alterations and hematologic malignancies with FGFR genetic alterations.
|CAS No.||872511-34-7 (Infigratinib);|
|Chemical Name||Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-N-methyl-|
|Infigratinib （Free Acid/Base）Parameters：|
|*：Calculated by ACD/Labs software V11.02.|